Infectious side effects of baricitinib: A big data analysis based on VigiBase

Dear Editor, Baricitinib (known as “Olumiant”), is an inhibitor of Janus- associated kinase 1 and 2 (JAK1 and JAK2) initially introduced for the treatment of rheumatoid arthritis (RA), and later for systemic lupus erythematosus (SLE), and atopic dermatitis [1]. The first approval of baricitinib was from the European Medicines Agency (EMA) as a mon- otherapy or combination therapy with methotrexate for patients with RA unresponsive to disease-modifying anti-rheumatic drugs (DMARDs)